Hematology, Department of Cellular Biotechnologies and Hematology, "Sapienza" University, Rome, Italy.
Oncologia Medica, Azienda Ospedaliera Pugliese Ciaccio, Catanzaro, Italy.
Leuk Res. 2014 Feb;38(2):198-203. doi: 10.1016/j.leukres.2013.11.009. Epub 2013 Nov 19.
In 45, ≤ 60 years old patients with CLL and an adverse biologic profile, a front-line treatment with Fludarabine and Campath (Alemtuzumab(®)) was given. The overall response rate was 75.5%, the complete response rate (CR) 24.4% with the lowest CR rates, 16.7% and 8.3%, in 11q and 17p deleted cases. The 3-year progression-free survival (PFS) and overall survival were 42.5% and 79.9%, respectively. PFS was significantly influenced by CLL duration, beta2-microglobulin, and improved by post-remissional stem cell transplantation. Front-line fludarabine and alemtuzumab showed a manageable safety profile and evidence of a benefit in a small series of CLL patients with adverse biologic features.
在 45 岁至 60 岁患有 CLL 且生物学特征不良的患者中，一线治疗采用氟达拉滨和坎帕斯（阿仑单抗）。总缓解率为 75.5%，完全缓解率（CR）为 24.4%，11q 和 17p 缺失病例的 CR 率最低，分别为 16.7%和 8.3%。3 年无进展生存（PFS）和总生存率分别为 42.5%和 79.9%。PFS 显著受 CLL 持续时间、β2-微球蛋白影响，经缓解后干细胞移植可改善。一线氟达拉滨联合阿仑单抗在具有不良生物学特征的小系列 CLL 患者中表现出可管理的安全性和获益证据。
